Rubius Therapeutics

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.